AZD8926

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522594

CAS#: 933785-68-3 (free base)

Description: AZD8926 is a potent and selective GSK3β inhibitor (glycogen synthase kinase-3β). AZD8926 has potential for treating several CNS disorders, such as Alzheimer’s disease (AD), schizophrenia, and chronic as well as acute neurodegenerative diseases.


Chemical Structure

img
AZD8926
CAS# 933785-68-3 (free base)

Theoretical Analysis

MedKoo Cat#: 522594
Name: AZD8926
CAS#: 933785-68-3 (free base)
Chemical Formula: C25H27F4N7O2
Exact Mass: 533.22
Molecular Weight: 533.532
Elemental Analysis: C, 56.28; H, 5.10; F, 14.24; N, 18.38; O, 6.00

Price and Availability

Size Price Availability Quantity
10mg USD -2
25mg USD -2
50mg USD -2
100mg USD -2
200mg USD -2
500mg USD -2
1g USD -1
2g USD -1
5g USD -1
10g USD -1
20g USD -1
50g USD -1
Bulk inquiry

Synonym: AZD8926; AZD-8926; AZD 8926.

IUPAC/Chemical Name: (4-((5-fluoro-4-(1-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(4-methylpiperazin-1-yl)methanone

InChi Key: JKLMQKZMMRJQCK-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H27F4N7O2/c1-34-8-10-35(11-9-34)22(37)16-2-4-17(5-3-16)32-24-31-14-19(26)21(33-24)20-15-30-23(25(27,28)29)36(20)18-6-12-38-13-7-18/h2-5,14-15,18H,6-13H2,1H3,(H,31,32,33)

SMILES Code: O=C(C1=CC=C(NC2=NC=C(F)C(C3=CN=C(C(F)(F)F)N3C4CCOCC4)=N2)C=C1)N5CCN(C)CC5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related: 933785-68-3 (AZD8926 free base) 933784-48-6 (AZD8926 HCl salt).

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 533.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. A Novel Scalable Process to the GSK3β Inhibitor AZD8926 Based on a Heterocyclic Ziegler Coupling
By Witt, Anette; Teodorovic, Peter; Linderberg, Mats; Johansson, Peter; Minidis, Anna
From Organic Process Research & Development (2013), 17(4), 672-678. | Language: English, Database: CAPLUS

2. A new combination of (a) an α-​4-​β-​2-​neuronal nicotinic agonist and (b) a glycogen synthase kinase 3 (GSK3) inhibitor
By Basun, Hans; Cox, Graham; Nordgren, Ingrid; Bencherif, Merouane
From PCT Int. Appl. (2009), WO 2009017455 A1 20090205. | Language: English, Database: CAPLUS

3. New therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958
By Basun, Hans; Cox, Graham; Nordgren, Ingrid
From PCT Int. Appl. (2009), WO 2009017453 A1 20090205. | Language: English, Database: CAPLUS

4. New therapeutic combination of a glycogen synthase kinase-​3 (GSK3) inhibitor and an α7-​nicotinic agonist
By Basun, Hans; Cox, Graham; Nordgren, Ingrid
rom PCT Int. Appl. (2009), WO 2009017454 A1 20090205. | Language: English, Database: CAPLUS

5. New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and​/or treatment of Alzheimer's disease
y Andersson, Lars; Arzel, Erwan; Berg, Stefan; Burrows, Jeremy; Hellberg, Sven; Huerta, Fernando; Pedersen, Torben; Rein, Tobias; Rotticci, Didier; Staaf, Karin; et al
From PCT Int. Appl. (2007), WO 2007040440 A1 20070412. | Language: English, Database: CAPLUS